Table 3.
The number of medications detected to have pDDIs and their corresponding ATC classes and codes (n = 6718).
First Level ATC Classification n (%) |
ATC Classification (Second Level) |
Frequency (%) |
---|---|---|
Alimentary Tract and Metabolism (A) n = 1714 (25.5%) |
Drugs for Acid Related Disorders (A02) | 149 (2.2%) |
Drugs for Functional Gastrointestinal Disorders (A03) | 16 (0.2%) | |
Drugs for Constipation (A06) | 2 (<0.1%) | |
Antidiarrheals (A07) | 5 (0.1%) | |
Drugs Used in Diabetes (A10) | 1147 (17.1%) | |
Vitamins (A11) | 112 (1.7%) | |
Minerals (A12) | 283 (4.2%) | |
Blood and Blood Forming Organs (B) n = 1069 (15.9%) |
Antithrombotic Agents (B01) | 1027 (15.3%) |
Antianemic Preparations (B03) | 42 (0.6%) | |
Cardiovascular System (C) n = 3130 (46.6%) |
Cardiac Therapy (C01) | 155 (2.3%) |
Antihypertensives (C02) | 24 (0.4%) | |
Diuretics (C03) | 1093 (16.2%) | |
Peripheral Vasodilators (C04) | 12 (0.2%) | |
Beta Blocking Agents (C07) | 549 (8.2%) | |
Calcium Channel Blockers (C08) | 204 (3%) | |
Agents Acting on The Renin-Angiotensin System (C09) | 811 (12.1%) | |
Lipid Modifying Agents (C10) | 282 (4.2%) | |
Genito Urinary System and Sex Hormones (G) | Urologicals (G04) | 51 (0.8%) |
Systemic Hormonal Preparations (H) n = 93 (1.4%) |
Corticosteroid for Systemic Use (H02) | 34 (0.5%) |
Thyroid Therapy (H03) | 59 (0.9%) | |
Antineoplastic and Immunomodulating Agents (L) | Immunosuppressants (L04) | 35 (0.5%) |
Musculo-skeletal System (M) n = 210 (3.1%) |
Anti-inflammatory and Antirheumatic Products (M01) | 39 (0.6%) |
Muscle Relaxants (M03) | 9 (0.1%) | |
Antigout Preparations (M04) | 84 (1.3%) | |
Drugs for Treatment of Bone Diseases (M05) | 78 (1.2%) | |
Nervous System (N) n = 138 (2%) |
Analgesics (N02) | 7 (0.1%) |
Antiepileptic (N03) | 79 (1.2%) | |
Anti-Parkinson (N04) | 12 (0.2%) | |
Psycholeptics (N05) | 3 (<0.1%) | |
Psychoanaleptics (N06) | 28 (0.4%) | |
Other Nervous System Drugs (N07) | 9 (0.1%) | |
Respiratory System (R) N = 278 (4.1%) |
Nasal Preparations (R01) | 38 (0.6%) |
Drugs for Obstructive Airway Diseases (R03) | 218 (3.2%) | |
Antihistamines for Systemic Use (R06) | 22 (0.3%) |